According to Fortune Business Insights, the global Intrauterine Devices Market size was valued at USD 4.48 billion in 2025. The market is projected to grow from USD 5.03 billion in 2026 to USD 12.55 billion by 2034, exhibiting a CAGR of 12.11% during the forecast period (2026–2034). The increasing demand for long-acting reversible contraceptives, growing awareness regarding family planning, regulatory approvals for extended device usage, and continuous product innovations are expected to drive market expansion. Furthermore, increasing investments in women's reproductive healthcare and improved accessibility to contraceptive solutions are creating significant growth opportunities worldwide.
The intrauterine devices industry is expanding as healthcare organizations increasingly promote effective family planning solutions. Rising awareness regarding unintended pregnancies and growing access to reproductive healthcare services are contributing to market development.
Manufacturers are focusing on improving device effectiveness, extending approved usage periods, and developing innovative contraceptive products.
For instance, in June 2024, Australia's Therapeutic Goods Administration approved the extension of Mirena's contraceptive usage duration from five years to eight years.
Such regulatory developments support consumer confidence and encourage the adoption of long-lasting contraceptive technologies.
However, high device costs, insertion expenses, and the availability of alternative contraceptive methods remain important challenges.
For detailed market insights: https://www.fortunebusinessinsights.com/intrauterine-devices-market-114775
One of the major trends influencing the intrauterine devices market is the growing preference for long-term contraceptive solutions. IUDs provide extended pregnancy prevention while remaining reversible, making them an important option in family planning programs.
Manufacturers are increasingly developing non-hormonal intrauterine devices to expand contraceptive choices.
In January 2025, Sebela Women's Health announced positive Phase 3 clinical study results for its investigational Copper 175mm² IUD, demonstrating its efficacy, safety, and tolerability during the first three years of use.
Companies are introducing improved insertion systems to simplify device placement.
In September 2024, CooperSurgical introduced a single-hand inserter designed for placing the hormone-free Paragard copper IUD.
These innovations are expected to improve convenience for healthcare professionals and support market adoption.